GLP-1 Drugs and SIBO: Ozempic, Wegovy, Mounjaro and Gut Motility

In short: GLP-1 drugsGLP-1 receptor agonist A class of diabetes and weight-loss medicines, such as semaglutide and tirzepatide, that copy a gut hormone released after meals. They slow the emptying of the stomach and movement through the small intestine. such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) slow down the stomach², and studies of this drug class show they slow the small intestine too³⁴. Slow gut movement is one of the main causes of SIBO, so a link is plausible. The largest study so far, of more than 432,000 people with type 2 diabetes, found that SIBO was diagnosed about twice as often in the first year on these drugs as on other diabetes medicines, although SIBO remained rare¹. No trial has tested whether GLP-1 drugs cause SIBO, and their common side effects overlap heavily with SIBO symptoms.

What GLP-1 drugs are

GLP-1 receptor agonists copy a gut hormone, glucagon-like peptide-1, that is released after meals. They are used to treat type 2 diabetes and obesity. Tirzepatide also acts on a second hormone, GIP, and is called a dual GLP-1/GIP agonist¹. Part of how these drugs work is by slowing digestion: the prescribing information for Wegovy states that semaglutide delays gastric emptying².

How they slow the small intestine

The effect is not limited to the stomach. Two studies measured the small intestine directly:

• In a 2016 randomized, double-blind crossover trial, 10 healthy people and 10 people with type 2 diabetes received an infusion of exenatide (an older GLP-1 drug) or saline. On exenatide, the duodenum had fewer contractions and less forward flow, and a glucose drink delivered into the small intestine moved through it more slowly. This happened even in people who felt little or no nausea³.
• In a 2026 study of 129 adults having capsule endoscopy (a swallowed camera), the capsule took a median of 311 minutes to pass through the small intestine in the 34 people on GLP-1 or GLP-1/GIP drugs, compared with 236 minutes in the 95 people not taking them. After adjusting for age, weight, diabetes and the reason for the test, the drugs were still linked to about 83 minutes longer transit⁴.

This matters because the small intestine relies on a regular cleansing wave, the migrating motor complex, to sweep bacteria out. When that movement slows, bacteria can build up. See our guide to what causes SIBO.

Do GLP-1 drugs cause SIBO?

The evidence so far comes from one large records study and a case report:

• A 2025 cohort study used health records from a global database to compare 216,173 adults with type 2 diabetes who started a GLP-1 or GLP-1/GIP drug with the same number who started other second-line diabetes medicines. People with major abdominal surgery, gastroparesisGastroparesis Delayed emptying of the stomach without a physical blockage, often caused by nerve damage such as in diabetes. or other strong SIBO risk factors were excluded. In the first year, SIBO was diagnosed in 0.177 per 1,000 patient-years on GLP-1 drugs, compared with 0.083 on other drugs, about twice the risk (hazard ratio 2.14), a result that only just reached statistical significance (p = 0.049). Over 5 years, the risk was still about double, but the result was not statistically significant¹.
• A 2024 case report describes a 35-year-old man who lost 22.7 kg on oral semaglutide, noticed worse lactose intolerance and new problems with gluten while taking it, and was diagnosed with SIBO six months after stopping. The authors describe the SIBO as possibly worsened by semaglutide⁶. A single case cannot show cause and effect.

The cohort study has important limits. It only shows an association, it relied on SIBO being diagnosed and recorded, and it only included people with type 2 diabetes, so it says nothing directly about people taking these drugs for weight loss¹. The absolute numbers are also small: fewer than 2 diagnoses per 10,000 people per year. Diabetes itself raises the risk of SIBO (see what causes SIBO), which is why the study compared people with diabetes on different drugs rather than with people without diabetes¹.

Side effects or SIBO?

Digestive side effects are very common on GLP-1 drugs, and many of them are also typical SIBO symptoms. In the adult weight-loss trials of Wegovy (semaglutide 2.4 mg), 73% of people on the drug reported digestive side effects, compared with 47% on placebo. These side effects increased during dose escalation².

Because of this overlap, symptoms that start soon after beginning a GLP-1 drug or raising the dose are more likely to be side effects. The 2025 cohort study’s authors suggest a breath test if symptoms suggest SIBO¹. Symptoms that persist long after the dose is stable are worth raising with your doctor.

A 2025 meta-analysis of 55 placebo-controlled trials with 106,395 people found that GLP-1 drugs increased the risk of gallstones (2 extra cases per 1,000 people) and probably of acid reflux (4 extra per 1,000), but did not appear to raise the risk of other serious digestive problems such as bowel obstruction or gastroparesis⁵. SIBO was not one of the outcomes studied.

Breath testing on a GLP-1 drug

Breath tests rely on a sugar drink moving through the gut at a typical pace. Because GLP-1 drugs slow the stomach and small intestine²⁴, the sugar may travel more slowly than usual. We found no study that has tested how this affects breath test results, so tell the clinic that orders your test which medicines you take. Do not stop a GLP-1 drug before a test without talking to the doctor who prescribed it.

What you can do

• Track timing. Note whether symptoms began with the drug or with a dose increase, and whether they settle once the dose is stable.
• Talk to your prescriber. A slower dose increase or a lower maintenance dose may be options. The label also notes that slower stomach emptying can affect how other tablets are absorbed².
• Look at other causes. Acid-suppressing medicines, diabetes and previous surgery all raise SIBO risk independently. See preventing SIBO relapse and SIBO after surgery.

Common questions

Does Ozempic cause SIBO?

It has not been shown. In a 2025 records study of people with type 2 diabetes, SIBO was diagnosed about twice as often in the first year on GLP-1 drugs as on other diabetes medicines, but it was still rare, and the study cannot prove cause and effect¹.

Can I take a GLP-1 drug if I already have SIBO?

There are no studies on this. Because these drugs slow gut movement³⁴, discuss your SIBO history with your prescriber before starting, especially if your SIBO is linked to slow motility or methane.

Does SIBO go away when you stop a GLP-1 drug?

Not necessarily. In the 2024 case report, SIBO was diagnosed six months after semaglutide was stopped⁶. If you have SIBO, it is treated in the usual way; see our treatment overview.